Skip to main content
Outlook Therapeutics, Inc. logo

Outlook Therapeutics, Inc. — Investor Relations & Filings

Ticker · OTLK ISIN · US69012T3059 LEI · 5493007AWUJ6HPMCBH11 US Manufacturing
Open in API
Filings indexed 780 across all filing types
Latest filing 2025-02-14 Major Shareholding Noti…
Country US United States of America
Listing US OTLK

About Outlook Therapeutics, Inc.

https://outlooktherapeutics.com/

Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of therapies for ophthalmic indications. The company's lead product candidate is ONS-5010 / LYTENAVA™ (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of retinal diseases, including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). If approved in the United States, it would be the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications. The therapy, under the brand name LYTENAVA™ (bevacizumab gamma), has received Marketing Authorization from the European Commission and the UK's MHRA for the treatment of wet AMD. The monoclonal antibody works by inhibiting vascular endothelial growth factor (VEGF).

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2025
Major Shareholding Notification
2025-02-14 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 14, 2025, reporting the issuance of a press release announcing financial results for the first fiscal quarter ended December 31, 2024. The text explicitly states that the press release is furnished as an exhibit and that the information is not deemed filed for certain regulatory purposes. The document itself does not contain detailed financial statements or substantive financial data but rather announces the release of financial results. The length is 3631 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as an Earnings Release (ER) announcement within a Form 8-K filing, which corresponds to the Earnings Release category.
2025-02-14 English
ARS
Annual Report
2025-02-10 English
FORM DEF 14A
Proxy Solicitation & Information Statement
2025-02-10 English
Director's Dealing 2025
Director's Dealing
2025-02-06 English
FORM PRE 14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A Proxy Statement filed with the SEC, specifically for the 2025 Annual Meeting of Stockholders of Outlook Therapeutics, Inc. It includes detailed information about proposals to be voted on, such as election of directors, approval of share issuance, amendment of certificate of incorporation, ratification of auditor selection, and advisory vote on executive compensation. The document contains extensive governance-related content including board nominees, corporate governance guidelines, and voting procedures. The presence of detailed proxy solicitation materials and voting instructions confirms this is a Proxy Solicitation & Information Statement, not an actual annual report or other filing type. The document length (15,000 characters) and content depth further support this classification.
2025-01-31 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.